Astellas Pharma Inc. (TYO:4503)
Japan
· Delayed Price · Currency is JPY | Market Cap | 4.13T |
| Revenue (ttm) | 2.14T |
| Net Income (ttm) | 291.54B |
| Shares Out | 1.79B |
| EPS (ttm) | 162.22 |
| PE Ratio | 14.22 |
| Forward PE | 12.55 |
| Dividend | 80.00 (3.35%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 10,866,600 |
| Average Volume | 4,925,510 |
| Open | 2,385.50 |
| Previous Close | 2,385.50 |
| Day's Range | 2,263.50 - 2,403.00 |
| 52-Week Range | 1,328.50 - 2,717.00 |
| Beta | 0.15 |
| RSI | 32.24 |
| Earnings Date | Apr 27, 2026 |
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with ch... [Read more]
Financial Performance
In fiscal year 2026, Astellas Pharma's revenue was 2.14 trillion, an increase of 11.87% compared to the previous year's 1.91 trillion. Earnings were 291.54 billion, an increase of 474.49%.
Financial StatementsNews
Full Year 2026 Astellas Pharma Inc Earnings Presentation Transcript
Full Year 2026 Astellas Pharma Inc Earnings Presentation Transcript
Astellas Pharma (ALPMY) Reports Strong FY Earnings with JPY 2139.2B Revenue
Astellas Pharma (ALPMY) Reports Strong FY Earnings with JPY 2139.2B Revenue
Astellas Pharma Earnings Call Transcript: Q4 2026
Record-high revenue and profit were achieved, driven by strong growth in strategic brands and robust cost optimization. FY 2026 guidance projects continued double-digit profit growth, increased R&D investment, and a higher dividend, with ongoing focus on pipeline expansion and operational efficiency.
Astellas, Pfizer Say FDA Grants Priority Review To SBLA For PADCEV Plus Keytruda
(RTTNews) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) on Monday said the U.S. Food and Drug Administration has granted Priority Review for a supplemental Biologics License Application for per...
Astellas Pharma Inc R&D Day Transcript
Astellas Pharma Inc R&D Day Transcript
Astellas Pharma Transcript: R&D Day 2026
Multiple flagship assets achieved proof of concept, with phase III trials underway in key indications. Strategic focus, disciplined portfolio management, and digital transformation are driving pipeline progress and operational efficiency, supporting long-term growth and financial targets.
What's Happening With VIR Stock?
Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer treatment, VIR-5500, along with encouraging P...
Astellas collaborates with Vir to develop its experimental prostate cancer drug
Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir Biotechn...
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Indian drugmaker Lupin said on Tuesday it has settled a patent infringement dispute with Japan's Astellas Pharma over the bladder disorder drug Mirabegron, allowing it to continue selling the product ...
Astellas Pharma Earnings Call Transcript: Q3 2026
Strong revenue and profit growth continued, driven by strategic brands and cost optimization. Upward guidance reflects robust demand, pipeline progress, and effective SG&A management, with further growth expected as new indications and global expansion advance.
Astellas Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference
A diversified portfolio of five strategic brands is set to drive growth and profitability after XTANDI's loss of exclusivity, with a focus on R&D innovation and financial discipline. The company targets a 30% operating profit margin by FY 2027, supported by cost optimization and a robust pipeline.
Astellas to Present at 44th Annual J.P. Morgan Healthcare Conference
TOKYO, Jan. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced it will present at the 44th Annual J.P. Morgan Healthcare Conference,...
Autobahn Labs Forms Strategic Partnership with Astellas to Accelerate Academic Discoveries into New Medicines
PALO ALTO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Autobahn Labs (“Autobahn”), a venture studio focused on transforming high-potential academic science into investable drug discovery and development...
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
- Data reflect new insights and precision oncology advancements in portfolio and pipeline - - Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-l...
Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting
- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3...
Astellas Pharma Earnings Call Transcript: Q2 2026
Revenue and core operating profit grew strongly year-on-year, driven by strategic brands and cost optimization. Full-year forecasts for revenue and profit were revised upward, with robust pipeline progress and continued focus on operational efficiency.
Astellas and the Internet's Favorite Grandma, Barbara 'Babs' Costello, Partner to Encourage Others to Get Ahead of Geographic Atrophy (GA)
Babs is sharing her family's history with progressive retinal disease GA, the advanced form of dry age-related macular degeneration (AMD), is a serious condition that may lead to irreversible vision l...
Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
Extensive and growing evidence continues to reinforce fezolinetant as an effective treatment for moderate to severe VMS associated with menopause Preliminary analysis from OPTION-VMS observational stu...
Astellas-Pfizer's combination therapy halves risk of death in bladder cancer patients
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, progression or death in patients suffering from a type of bladder cancer, the comp...
Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society
TOKYO , Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-horm...
Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO , Oct. 8, 2025 /PRNew...
Astellas Announces Top Management Personnel Change
TOKYO , Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its Top Management structure, effective O...
Astellas Pharma Earnings Call Transcript: Q1 2026
Q1 FY2025 saw strong revenue and profit growth, led by strategic brands and cost optimization. Pipeline progress and new licensing agreements support future growth, while cost savings are being reinvested. Full-year guidance will be reviewed after Q2.
Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
- Supporting Korean Startups' Drug Discovery Research and Global Expansion - - First Pharmaceutical Company from Japan to Actively Support the Operation of the Program - TOKYO , July 17, 2025 /PRNewsw...